CClinicalTrials.gg
CompletedNCT05367167Updated Jan 3, 2023

The Effect of Fibromyalgia Syndrome Accompanying Obstructive Sleep Apnea Syndrome on Clinical Findings

An observational study in Obstructive Sleep Apnea and Fibromyalgia, sponsored by Kirsehir Ahi Evran Universitesi. Completed at 1 site in Turkey. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-01-03.

Sponsored by Kirsehir Ahi Evran Universitesi · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
69
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Fibromyalgia Syndrome (FMS) is a chronic disease that lasts for at least three months and is characterized by various symptoms such as tender points, widespread pain in the musculoskeletal system, sleep disturbance and fatigue. Obstructive sleep apnea (OSAS) is a disease characterized by repeated upper airway obstruction during sleep. Sleep disorders negatively affect the lives of individuals. The prevalence of OSAS is between 1-5% in studies and it is more common in men than in women. Fatigue, anxiety, depression and sleep disturbance are also common in patients with fibromyalgia. Likewise, the presence of symptoms such as musculoskeletal pain in patients with OSAS suggests that these two diseases may be related to each other. We planned this study to show the relationship between OSAS and fibromyalgia (FM).

Read the detailed description

Our research will be carried out on patients diagnosed with OSAS after being evaluated in the sleep laboratory of the Research Hospital Department of Chest Diseases. Fibromyalgia screening will be performed on participants who are diagnosed with OSAS and accepted to participate in the study. Patients with FM according to the 2010 American College of Rheumatology diagnostic criteria will be divided into two groups as FM patients (case group) and patients who do not meet these criteria (control group). Sleep laboratory results and demographic data of all patients will be recorded. In addition, anxiety, depression and fatigue levels will be evaluated with scales. Fibromyalgia impact questionnaire will be applied to fibromyalgia patients. Our study is a cross-sectional prospective case-control study. It is not a treatment research, an interventional application will not be made to the patients.

Our hypothesis is that OSAS patients with FMS may have more fatigue, anxiety, depression, lower algometer values, and more severe OSAS findings in polysomnographic data.

02

Conditions studied

  • Obstructive Sleep Apnea
  • Fibromyalgia

Keywords

  • Polysomnography
  • Obstructive Sleep Apnea
  • Fibromiyalgia
03

In context

Fibromyalgia

1,335 studies on the registry are indexed under Fibromyalgia; 265 are open to participants now.

This study's enrollment of 69 is below the median of 100 across 270 observational studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

Kirsehir Ahi Evran Universitesi is the lead sponsor of 133 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Our research will be carried out in patients diagnosed with OSAS after being evaluated in the sleep laboratory of the Kırşehir EAH Department of Chest Diseases. Fibromyalgia screening will be performed on participants who are diagnosed with OSAS and accepted to participate in the study. Patients who were diagnosed with FM according to the 2010 American College of Rheumatology diagnostic criteria will be divided into two groups as FM patients (case group) and patients who do not meet these criteria will be divided into two groups as FM (control group).

Inclusion criteria

1.18-60 years old 2. Diagnosed with OSAS in sleep laboratory examinations 3. Agree to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy
  2. Neuropsychiatric disease
  3. Inflammatory Rheumatic Diseases
  4. Morbid obesity
  5. Using a device with a previous diagnosis of OSAS
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
69 participants (actual)
Patient registry
No

Groups and cohorts

  • Case group

    Patients who meet the 2010 American College of Rheumatology diagnostic criteria and were diagnosed with OSAS in the sleep laboratory will be considered as the case group.

  • Control group

    Patients who did not meet the 2010 American College of Rheumatology diagnostic criteria and were diagnosed with OSAS in the sleep laboratory will be considered as the control group.

06

What researchers measure

Primary outcomes

  1. Fatigue Severity Scale

    "Fatigue Severity Scale" was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established.

    Time frame: 0 day (baseline)

  2. Fibromyalgia Impact Scale

    The fibromyalgia levels of the participants will be evaluated with the Fibromyalgia Impact Scale. High scores indicate increased disease activity. Consists of 10 questions Maximum score is 80. Turkish validity and reliability was done

    Time frame: 0 day (baseline)

  3. Beck Anxiety and Depression Inventory.

    Anxiety and depression levels will be evaluated with the Beck Anxiety and Depression Inventory. Turkish validity and reliability were done.Beck Depression Inventory (BDI) is a 21-item self-assessment scale that measures characteristic attitudes and symptoms of depression. The application takes about 10 minutes to complete. It is designed for people aged 13 and over. High scores report an increased level of depression.Beck anxiety scale This test, which consists of 21 optional questions, is accepted as an internationally valid tool used to measure the severity of anxiety in individuals.Each item marked on the Beck anxiety scale has a score. None is 0 points, mild 1 point, moderate 2 points, and severe 3 points. In this way, these scores are summed after 21 questions are marked. High scores indicate an increased level of anxiety.

    Time frame: 0 day (baseline)

  4. visual analog scale

    Pain levels will be evaluated with a visual analog scale. The VAS is a scale that evaluates the severity of pain with the Likert scale. Increased scores indicate severe pain.

    Time frame: 0 day (baseline)

  5. Algometer.

    The pain threshold of all patients will be measured with an algometer. Measurement with an algometer is not an invasive measurement method. It shows the patient's pain sensitivity numerically according to the applied pressure.

    Time frame: 0 day (baseline)

  6. Demografic Datas

    Sex, chronic disease, smoking

    Time frame: 0 day (baseline)

  7. BMI

    64 / 5.000 Çeviri sonuçları Body mass index will be calculated by measuring height (cm), weight (kg),

    Time frame: 0 day (baseline)

  8. Polisomnografi - SLEEP LATENCE

    Sleep latency time will be measured in polysomnography

    Time frame: 0 day (baseline)

  9. Polisomnografi -SLEEP ACTIVITY

    Sleep efficiency will be measured during polysomnography

    Time frame: 0 day (baseline)

  10. Polisomnografi -REM time

    REM time will be measured in minutes during polysomnography

    Time frame: 0 day (baseline)

  11. Polisomnografi -NREM STAGES

    During polysomnography, NREM stages will be measured at 1 min, 2 min, and 3 min.

    Time frame: 0 day (baseline)

  12. Polisomnografi - NUMBERS OF APNE

    Numbers of apnea will be recorded in polysomnographic measurements.

    Time frame: 0 day (baseline)

  13. Polisomnografi -NUMBER OF HYPOPNEA

    Numbers of hypopnea will be recorded in polysomnographic measurements.

    Time frame: 0 day (baseline)

  14. Polisomnografi -Apnea hypopnea index (AHI) REM, NONREM in polysomnography; Apnea hypopnea index (AHI) will be evaluated on a supine, non-supine basis.

    Apnea hypopnea index (AHI) will be evaluated as REM, NONREM, Supine, non-supine in polysomnography.According to the AHI level; It will be classified as SIMPLE SNORING (AHİ\<5), LIGHT OSAS (AHİ 5-15), MEDIUM OSAS (AHİ 15-30), HEAVY OSAS (AHİ 30+ )

    Time frame: 0 day (baseline)

  15. Polisomnografi -OXYGEN DESATURATION INDEX

    Minimum oxygen saturation and average oxygen saturation will be measured in polysomnography.

    Time frame: 0 day (baseline)

07

Study locations

1 site
  • Ahi Evran University
    Kırşehir, City Centre 40100, Turkey
08

References and documents

Publications

  • Meresh ES, Artin H, Joyce C, Birch S, Daniels D, Owens JH, La Rosa AJ, Rao MS, Halaris A. Obstructive sleep apnea co-morbidity in patients with fibromyalgia: a single-center retrospective analysis and literature review. Open Access Rheumatol. 2019 Apr 29;11:103-109. doi: 10.2147/OARRR.S196576. eCollection 2019. PubMed 31118843 ↗
  • Koseoglu HI, Inanir A, Kanbay A, Okan S, Demir O, Cecen O, Inanir S. Is There a Link Between Obstructive Sleep Apnea Syndrome and Fibromyalgia Syndrome? Turk Thorac J. 2017 Apr;18(2):40-46. doi: 10.5152/TurkThoracJ.2017.16036. Epub 2017 May 1. PubMed 29404158 ↗
  • Mutlu P, Zateri C, Zohra A, Ozerdogan O, Mirici AN. Prevalence of obstructive sleep apnea in female patients with fibromyalgia. Saudi Med J. 2020 Jul;41(7):740-745. doi: 10.15537/smj.2020.7.25165. PubMed 32601643 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05367167
Lead sponsor
Kirsehir Ahi Evran Universitesi
Responsible party
Basak Cigdem Karacay (Principal Investigator, Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
May 10, 2022
Start date
Apr 8, 2022
Primary completion
Nov 28, 2022
Completion
Nov 28, 2022
Last update
Jan 3, 2023

Study contacts

Basak Cigdem Karacay, Asisst Prof
principal investigator · Kirsehir Ahi Evran Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion